Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Wolf‐Karsten Hofmann, Jörg Schubert et al.|Blood|2011Cited by 289
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemiaRüdiger Hehlmann, Aloïs Gratwohl, Ute Berger et al.|Blood|2007Cited by 168
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)Jason Gotlib, Srđan Verstovšek, Jean‐Jacques Kiladjian et al.|Blood|2021Cited by 51
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (<i>JAK2</i>) V617F and KIT proto‐oncogene, receptor tyrosine kinase (<i>KIT</i>) D816V mutationsNicole Naumann, Juliana Schwaab, Johannes Lübke et al.|British Journal of Haematology|2021Cited by 17
FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated PatientsSrđan Verstovšek, Jean‐Jacques Kiladjian, Jason Gotlib et al.|Blood|2022Cited by 14